Professional Documents
Culture Documents
Aspirin
Aspirin
TIME: 15 MINUTES
INSTRUCTIONS TO CANDIDATES:
Abstract
In the last few years, the concept of aspirin resistance has been
largely emphasised in the medical literature, although its definition,
mechanism, and specific guidelines for its management remain
unclear. Aspirin displays good antithrombotic activity. Various
laboratory parameters assessing the efficacy of aspirin like
bleeding time, platelet reactivity, thromboxane-A2 (TX-A2)
production, and measurement of platelet aggregation, have
confirmed the lack of its uniform effect on the platelets. Few
studies have reported aspirin resistance to the tune of 5 - 45%.
Various extrinsic and intrinsic factors influence the resistance.
Numerous studies reveal that aspirin resistance can be overcome by
combining it with another antithrombotic agent, i.e., clopidogrel.
Further, clopidogrel resistance has also been reported. So, much is
expected in the field of diagnostic tests in order to know the true
picture of aspirin resistance.
Go to “1” “2” “3” “4” “5” “6” “7” “8” “9” “10”
Questions “11” “12” “13” “14” “15” “16” “17” “18” “19” “20”
Text B
Mechanisms of aspirin resistance
The exact mechanisms are not clear:
True aspirin resistance:
The proposed factors for this type of resistance include:
i. Decreased bioavailability of aspirin.
ii. Accelerated platelet turnover introducing newly formed, non-
aspirinated platelets into the blood stream.
iii. Competition of aspirin with other NSAIDs (like ibuprofen)
preventing aspirin access at Serine 530 of Cox-I.
iv. Transcellular formation of TxA2 by aspirinated platelets from
PGH2 released by other blood cells or vascular cells.
v. TxA2 production by aspirin insensitive Cox-2 in newly formed
platelets or other cells.
vi. (Theoretical) presence of variant Cox-I which is less sensitive to
aspirin inhibition.
vii. Poor compliance by the patient.
Go to “1” “2” “3” “4” “5” “6” “7” “8” “9” “10”
Questions “11” “12” “13” “14” “15” “16” “17” “18” “19” “20”
Text C
Aspirin dosage
According to the Antithrombotic Trialists’ Collaboration, daily
doses of aspirin (75 - 150 mg) are as effective as higher doses for
prevention of thrombotic events and are associated with low risk of
bleeding. Bornstein et al in their study have shown that even 100
mg of aspirin completely inhibits Cox-1 enzyme, thus further
substantiating the fact that patients with resistance established
during low dose aspirin therapy may respond to higher doses. The
results of this study showed that aspirin in doses of 500 mg/day
significantly prolonged the time between first and second stroke (p
= 0.002) compared with lower doses. Helgason et al revealed that
an increase in the dose of aspirin to 625 that suboptimal reduction
of urinary 11-dehydro TxB2 level during aspirin treatment is
associated with increased risk for future MI and cardiovascular
death, thereby suggesting that “true aspirin resistance” may be a
clinically relevant phenomenon. Inadequate inhibition of TxA2
biosynthesis by aspirin can be seen in patients on ibuprofen
therapy, because of competition of these 14 mg/day in five patients
who were aspirin resistant with 325 mg/day showed aspirin
sensitivity. Another study has revealed that these patients remained
resistant with aspirin 1,300 mg. This shows that inadequate dose
cannot explain aspirin resistance in all subjects.
Go to “1” “2” “3” “4” “5” “6” “7” “8” “9” “10”
Questions “11” “12” “13” “14” “15” “16” “17” “18” “19” “20”
Text D
Management of aspirin resistance
Currently there are no specific guidelines for the management of
aspirin resistance. The first step is to enquire about the patient’s
compliance. Regarding optimal aspirin dosing, it is controversial.
No convincing data are available showing that the antithrombotic
effect of aspirin is dose related. The meta-analysis by Anti-
Thrombotic Trialist’s Collaboration refuted the claim that high
doses of aspirin (500 - 1,500 mg/day) were effective than low
doses (75 - 150 mg/day). Other method to manage aspirin
resistance is by addition of another antiplatelet agent – clopidogrel,
because CAPRIE trial has shown greater benefit of combination of
aspirin and clopidogrel compared with aspirin alone. The
combination of aspirin with clopidogrel is an ideal one since
clopidogrel inhibits another pathway of platelet activation.
However, till date, it is not clear whether the superiority of a
combination of clopidogrel and aspirin over aspirin is due to
clopidogrel compensation for aspirin non-responders. Resistance to
even clopidogrel has been reported, which is associated with an
increased risk of recurrent thrombotic events in patients with acute
MI.
.
Go to “1” “2” “3” “4” “5” “6” “7” “8” “9” “10”
Questions “11” “12” “13” “14” “15” “16” “17” “18” “19” “20”
Part A
TIME: 15 minutes
• Look at the four texts, A-D, in the separate Text Booklet.
• For each question, 1-20, look through the texts, A-D, to find the
relevant information.
• Write your answers on the spaces provided in this Question
Paper.
• Answer all the questions within the 15-minute time limit.
• Your answers should be correctly spelt.
QUESTIONS
Questions 1-7
For each question, 1-7, decide which text (A, B, C or D) the information
comes from. You may use any letter more than once.
Questions 8-13
Answer each of the questions, 8-13, with a word or short phrase from one of
the texts. Each answer may include words, numbers or both.
8. How much mg of aspirin is minimum required to completely
inhibit Cox-1 enzyme?
Go to “Text A” “Text B” “Text C” “Text D”
9. Which patients show inadequate inhibition of TxA2 biosynthesis by
aspirin?
Go to “Text A” “Text B” “Text C” “Text D”
10. Name the antiplatelet agent used to manage aspirin resistance?
Go to “Text A” “Text B” “Text C” “Text D”
11. What are responsible for transcellular formation of TxA2?
Go to “Text A” “Text B” “Text C” “Text D”
12. What is the daily doses range of aspirin according to the
Antithrombotic Trialists’Collaboration?
Go to “Text A” “Text B” “Text C” “Text D”
13. Which trial has shown greater benefit of combination of aspirin
and clopidogrel?
Go to “Text A” “Text B” “Text C” “Text D”
Questions 14-20
Complete each of the sentences, 14-20, with a word or short phrase
from one of the texts. Each answer may include words, numbers or
both.
14. Aspirin displays good _____ activity.
Go to “Text A” “Text B” “Text C” “Text D”
15. Few studies have reported aspirin resistance to the tune of
_____.
Go to “Text A” “Text B” “Text C” “Text D”
16. TxA2 may be produced by aspirin insensitive _____ in newly
formed platelets or other cells.
Go to “Text A” “Text B” “Text C” “Text D”
17. Increase in the dose of aspirin to 625 is associated with
increased risk for future MI and _____.
Go to “Text A” “Text B” “Text C” “Text D”
18. Inadequate inhibition of TxA2 ______ by aspirin can be seen in
patients on ibuprofen therapy.
Go to “Text A” “Text B” “Text C” “Text D”
19. The first step in management of aspirin resistance is to enquire
about the patient’s ______.
Go to “Text A” “Text B” “Text C” “Text D”
20. The combination of _____ with clopidogrel is an ideal one.
Go to “Text A” “Text B” “Text C” “Text D”
Answer Key
“Practice Test 1”
Practice Test 2
READING SUB-TEST – QUESTION PAPER: PART B & C
TIME: 45 MINUTES
INSTRUCTIONS TO CANDIDATES:
Part B
In this part of the test, there are six short extracts relating to the
work of health professionals. For questions 1-6, choose the answer
(A, B or C) which you think fits best according to the text.
Anaesthetic Machines
The anaesthetic machine (or anaesthesia machine in America) is used by
anaesthesiologists and nurse anaesthetists to support the administration of
anaesthesia. The most common type of anaesthetic machine is the
continuous-flow anaesthetic machine, which is designed to provide an
accurate and continuous supply of medical gases (such as oxygen and nitrous
oxide), mixed with an accurate concentration of anaesthetic vapour (such as
halothane or isoflurane), and deliver this to the patient at a safe pressure and
flow. Modern machines incorporate a ventilator, suction unit, and patient
monitoring devices.
1. The manual is giving information about
A. how to use anaesthetic machines
B. types of anaesthetic machines
C. an overview of anaesthetic machines
mHealth
The use of mobile technologies for data collection about individuals and
interactive information services are a part of a growing area of eHealth called
mHealth. The GOe published a volume on this subject in 2011 which
documents the uptake of mHealth worldwide by types of initiatives and main
barriers to scale. Mobile technologies are emerging as a powerful tool for
health information transfer including making patient information portable.
Such technologies can be more fully utilized through electronic patient
information such as EMRs and EHRs. Electronic records will work best,
however, if there are standards in place for their use and interoperability.
Answer Key
“Practice Test 2”
Practice Test 3
READING SUB-TEST – QUESTION PAPER: PART B & C
TIME: 45 MINUTES
INSTRUCTIONS TO CANDIDATES:
Answer Key
“Practice Test 3”
Practice Test 4
READING SUB-TEST – QUESTION PAPER: PART B & C
TIME: 45 MINUTES
INSTRUCTIONS TO CANDIDATES:
Answer Key
“Practice Test 4”